|Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study|
JM Chan, MJ Stampfer, E Giovannucci, PH Gann, J Ma, P Wilkinson, ...
Science 279 (5350), 563-566, 1998
|American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity|
LH Kushi, C Doyle, M McCullough, CL Rock, W Demark‐Wahnefried, ...
CA: a cancer journal for clinicians 62 (1), 30-67, 2012
|Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends|
R Etzioni, DF Penson, JM Legler, D Di Tommaso, R Boer, PH Gann, ...
Journal of the National Cancer Institute 94 (13), 981-990, 2002
|A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer|
PH Gann, CH Hennekens, MJ Stampfer
Jama 273 (4), 289-294, 1995
|Prospective study of sex hormone levels and risk of prostate cancer|
PH Gann, CH Hennekens, J Ma, C Longcope, MJ Stampfer
JNCI: Journal of the National Cancer Institute 88 (16), 1118-1126, 1996
|Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis|
PH Gann, J Ma, E Giovannucci, W Willett, FM Sacks, CH Hennekens, ...
Cancer research 59 (6), 1225-1230, 1999
|Prostate specific antigen best practice statement: 2009 update|
KL Greene, PC Albertsen, RJ Babaian, HB Carter, PH Gann, M Han, ...
The Journal of urology 182 (5), 2232-2241, 2009
|Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer|
JM Chan, MJ Stampfer, J Ma, P Gann, JM Gaziano, M Pollak, ...
Journal of the National Cancer Institute 94 (14), 1099-1106, 2002
|Low-dose aspirin and incidence of colorectal tumors in a randomized trial|
PH Gann, JAE Manson, RJ Glynn, JE Buring, CH Hennekens
JNCI: Journal of the National Cancer Institute 85 (15), 1220-1224, 1993
|Abnormal glucose metabolism and pancreatic cancer mortality|
SM Gapstur, PH Gann, W Lowe, K Liu, L Colangelo, A Dyer
Jama 283 (19), 2552-2558, 2000
|Role of diet in prostate cancer development and progression|
JM Chan, PH Gann, EL Giovannucci
Journal of Clinical Oncology 23 (32), 8152-8160, 2005
|Prospective study of plasma fatty acids and risk of prostate cancer|
PH Gann, CH Hennekens, FM Sacks, F Grodstein, EL Giovannucci, ...
JNCI: Journal of the National Cancer Institute 86 (4), 281-286, 1994
|Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study|
JM Chan, MJ Stampfer, J Ma, PH Gann, JM Gaziano, EL Giovannucci
The American journal of clinical nutrition 74 (4), 549-554, 2001
|Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies|
AW Roddam, NE Allen, P Appleby, TJ Key, L Ferrucci, HB Carter, ...
Annals of internal medicine 149 (7), 461-471, 2008
|Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia|
KT McVARY, A Rademaker, GL Lloyd, P Gann
The Journal of urology 174 (4 Part 1), 1327-1333, 2005
|Colorectal cancer mortality and factors related to the insulin resistance syndrome|
LA Colangelo, SM Gapstur, PH Gann, AR Dyer, K Liu
Cancer Epidemiology and Prevention Biomarkers 11 (4), 385-391, 2002
|Serum androgen concentrations in young men: A longitudinal analysis of associations with age, obesity, and race.: The CARDIA male hormone study|
SM Gapstur, PH Gann, P Kopp, L Colangelo, C Longcope, K Liu
Cancer Epidemiology and Prevention Biomarkers 11 (10), 1041-1047, 2002
|A randomized trial of single-and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis|
PH Gann, FA Neva, AA Gam
Journal of Infectious Diseases 169 (5), 1076-1079, 1994
|Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians.|
J Ma, MJ Stampfer, PH Gann, HL Hough, E Giovannucci, KT Kelsey, ...
Cancer Epidemiology and Prevention Biomarkers 7 (5), 385-390, 1998
|Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.|
PH Gann, J Ma, CH Hennekens, BW Hollis, JG Haddad, MJ Stampfer
Cancer Epidemiology and Prevention Biomarkers 5 (2), 121-126, 1996